Crush stenting in treating coronary bifurcate lesions: Paclitaxel eluting stents versus sirolimus eluting stents

Chinese Medical Journal

Volumn 121, Issue 6, 2008, Pages 528-533

  Chen, Shao Liang ^a   Zhang, Jun Jie ^a   Ye, Fei ^a   Chen, Yun Dai ^b   Zhu, Zhong Sheng ^a   Lin, Song ^a   Tian, Nai Liang ^a   Liu, Zhi Zong ^a   Fang, Wei Yi ^c   Sun, Xue Wen ^a   Hu, Da Yi ^d   Kwan, Tak W ^e  

^a NANJING MEDICAL UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c SHANGHAI CHEST HOSPITAL   (China)

^d PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^e BETH ISRAEL MEDICAL CENTER   (United States)

Author keywords

Bifurcate lesions; Crush stenting; Drug eluting stent

Indexed keywords

PACLITAXEL; RAPAMYCIN;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY BIFURCATE LESION; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; REVASCULARIZATION; SURVIVAL RATE;

EID: 41649113542     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00029330-200803020-00012     Document Type: Article

References (24)

1. Morice MC, Serruys PW, Sousa JE, Fajadelt J, Ban ayashi E, Perin M, et al. A randomized comparison of a sirolimus eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346; 1773-1780.
2. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, et al. SIRIUS investigators, sirolimus eluting stents versus standard stents in patients in a native coronary artery. N Engl J Med 2003; 349: 1315-1323.
3. O'Neill WW, Leon MB. Drug eluting stents costs versus clinical benefit. Circulation 2003; 107: 3008-3011.
4. Al Suwadi J, Yeh W, Cohen HA, Detre KM, Williams DO, Holmes DR Jr. Immediate and one year outcome in patients with coronary bifurcate lesions in the modern era (NHLBI dynamic registry). Am J Cardiol 2001; 87: 1139-1144.
5. Colombo A, Moses JW, Morice MC, Ludwig J, Holmes DR Jr, Spanos V, et al. Randomized study to evaluate sirolimus eluting stents implanted at coronary bifurcate lesions. Circulation 2004; 109: 1244-1249.
6. Lefevre T, Louvard Y, Morice MC, Dumas P, Loubeyre C, Benslimane A, et al. Stenting of bifurcate lesions: classification, treatments, and results. Catheter Cardiovasc Interv 2000; 49: 274-283.
7. Colombo A, Stankovic G, Orlic D, Corvaja N, Liistro F, Airodi F, et al. Modified T stenting technique with crushing for bifurcate lesions: immediate results and 30 day outcome. Catheter Cardiovasc interv 2003; 60: 145-151.
8. Ge L, Iakovou I, Cosgrave J, Agostoni P, Airoldi F, Sangiorgi GM, et al. Treatment of bifurcate lesions with two stents: one year angiographic and clinical followup of crush versus T stenting. Heart 2006; 92: 371-376.
9. Moussa I, Costa RA, Leon MB, Lansky AJ, Lasic Z, Cristea E, et al. A prospective registry to evaluate sirolimus eluting stents implanted at coronary bifurcate lesions using the "crush technique". Am J Cardiol 2006; 97: 1317-1321.
10. Ge L, Airoldi F, Iakovou I, Cosgrave J, Michev I, Sangiorgi GM, et al. Clinical and angiographic outcome after implantation of drug eluting stents in bifurcate lesions with the crush stent technique: importance of final kissing balloon postdilation. J Am Coll Cardiol 2005; 46: 613-620.
11. Louvard Y, Lefevre T, Morice MC. Percutaneous coronary intervention for bifurcation coronary disease. Heart 2004; 90: 713-722.
12. Yamashita T, Nishida T, Adamian MG, Briguori C, Vaghetti M, Corvaja N, et al. Bifurcate lesions: two stents versus one stent: immediate and followup results. J Am Coll Cardiol 2000; 35: 1145-1151.
13. Assali AR, Assa HV, Ben-Dor I, Teplistky I, Solodkv A, Brosh D, et al. Drug eluting stents in bifurcate lesions: to stent one branch or both? Catheter Cardiovasc Interv 2006; 68: 891-896.
14. Dzavik V, Kharbanda R, Ivanov J, Ing DJ, Bsc SB, Mackie K, et al. Predictors of long-term outcome after crush stenting of coronary bifurcate lesions: importance of the bifurcation angle. Am Heart J 2006; 152: 762-759.
15. Steigen TK, Maeng M, Wiseth R, Erglis A, Kumsars I, Narbute I, et al. for the Nordic PCI study group. Randomized study on simple versus complex stenting of coronary artery bifurcate lesions: the Nordic bifurcation study. Circulation 2006; 114: 1955-1961.
16. Windecker S, Remondino A, Eberli FR, Juni P, Raber L, Wenaweser P, et al. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med 2005; 353: 653-662.
17. Dibra A, Kastrati A, Mehilli J, Pache J, Schuhlen H, Beckerath N, et al. For the ISAR-DIABETES study investigators. Paclitaxel eluting or sirolimus eluting stents to prevent restenosis in diabetic patients. N Engl J Med 2005; 353: 663-670.
18. Morice MC, Colombo A, Meier B, Serruys P, Tamburino C, Guagliumi CT, et al. Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial. JAMA 2006; 295: 895-904.
19. Mario CD, Morici N, Godlino C, Goktekin O, Tamburino C, Barbagallo R, et al. Predictors of restenosis after treatment of bifurcational lesions with paclitaxel-eluting stents: a multicenter prospective registry of 150 consecutive patients. Catheter Cardiovasc Interv 2007; 69: 416-424.
20. Hoye A, Iakovou I, Ge L, van Mieghem CA, Ong AT, Cosqrave J, et al. Long-term outcomes after stenting of bifurcate lesions with the "crush" technique: predictors of an adverse outcome. J Am Coll Cardiol 2006; 47: 1949-1958.
21. Pan MP, Suarez de Lezo J, Medina A, Romero M, Delgado A, Segura J, et al. Drug eluting stents for the treatment of bifurcate lesions: a randomized comparison between paclitaxel and sirolimus stents. Am Heart J 2007; 153: 15.e1-15.e7.
22. Tanabe K, Serruys PW, Degertekin M, Guagliumi G, Grube E, Chan C, et al. For the TAXUS II study group. Chronic arterial responses to polymer-controlled paclitaxel-eluting stents: comparison with bare metal stents by serial intravascular ultrasound analysis: data from the randomized TAXUS-II trial. Circulation 2004; 109: 196-200.
23. Weissman NJ, Koglin J, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, et al. Polymer-based paclitaxel-eluting stents reduce in stent neointimal tissue proliferation: a serial volumetric intravascular ultrasound analysis from the TAXUS-IV trial. J Am Coll Cardiol 2005; 45: 1201-1205.
24. Finn AV, Kolodgie FD, Harnek J, Guerrero LJ, Acampado E, Tefera K, et al. Diffferential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents. Circulation 2005; 112: 270-278.